In this article
CAR-T cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers, by repairing or reconstructing damaged genetic materials to achieve a therapeutic effect. Since the FDA approved the first CAR-T therapy, Kymriah, in 2017, the CAR-T market has grown rapidly, with the global market size projected to increase from USD 10 million in 2017 to USD 9.05 billion in 2025, at a compound annual growth rate of 55% from 2019 to 2025. CAR-T therapy can be divided into autologous CAR-T cell therapy, which employs the patient's own immune cells, and allogeneic CAR-T cell therapy, which employs T cells from donor blood. The therapy has reached unprecedented success in treating B-cell cancers resistant to chemotherapy, including R/R B-ALL, NHL, and MM, with CD19-targeting and BCMA-targeting CAR-T therapies achieving the greatest clinical success among all CAR-T approaches.
The United States pioneered the development of the CAR-T industry, but by the middle of the 2010s, China had learned quickly and was catching up, driven primarily by strong government support for the development of a cell and gene therapy ecosystem. Following the prioritization of biotechnology in the thirteenth five-year plan, the Chinese government emphasized accelerating innovation in biotech industries including cell therapy, and Chinese cell-therapy companies raised approximately USD 2.4 billion in funding between 2018 and 2021 at a compound annual growth rate of 45%. The number of CAR-T therapy trials in China surpassed those in the United States by 2018, and as of June 2022, Chinese companies had conducted 342 clinical CAR-T trials. The domestic CAR-T market is projected to grow from CNY 0.2 billion in 2021 to CNY 28.9 billion in 2030, at a CAGR of 45% from 2022 to 2030. Two CAR-T products have received commercial approval — Yescarta in June 2021 and Relma-cel in September 2021 — while domestic players such as Legend Biotech, IASO Biotherapeutics, and CARsgen Therapeutics have made significant breakthroughs, particularly in BCMA CAR-T therapy and solid tumour treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.